6,678 trials
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Mean Change From Baseline in Serum Potassium Levels Over 24 Hours — 4.3; 0.25; 0.60; 0.49 mmol/L
HIV
Primary: Biomedical Prevention Covered Time — 69.7; 13.3 % of days
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Adverse Events — 564 Participants
Metastatic Castration Resistant Prostate Cancer
Primary: Number of Participants With Treatment- Emergent Adverse Events (TEAEs) — 36 Participants
Hunter Syndrome
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuation Due to TEAEs and Death — 5; 1; 1; 0 Participants
Multiple Sclerosis
Primary: Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) During Year 3 to 4 — 54.23 percentage of participants
Airway Inflammation · Asthma
Primary: Fractional Exhaled Nitric Oxide (FeNO) — 8.67; 9.01 parts per billion (ppb)
Multiple Sclerosis
Primary: Relapses Post Partum — 2; 7 Participants
Colorectal Cancer
Primary: Colonoscopy Completion Rate — 591; 600 Participants
Brain Imaging · Whole Body Imaging
Primary: Motion Correction — 57.4; 13.9 percentage of voxels
Nail Psoriasis
Primary: Clinical Improvement in Nail Thickness of Target Nail at Week 24 Compared to Baseline. — 2 Participants who experienced improvement
Cellulitis
Primary: Patient Recruitment Rate — 51.5 percentage of eligible patients
Poor Thymic Function · Immunodeficiency · Athymia
Primary: Survival Rate at End of 1 Year — 90.9 percentage of participants
Immune Thrombocytopenia
Primary: Safety and Tolerability (Adverse Events) — 35; 6; 1; 15 Participants
Type 1 Diabetes Mellitus
Primary: CGM Measured Time <70 mg/dL — 1.58; 1.67; 2.57 % time <70 mg/dL